Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

12.14 -0.28 (-2.25%)

Delayed Quote Updated: 12:38 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Design Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Stocks That Hit 52-Week Lows On Wednesday ↗

February 15, 2023

On Wednesday, 35 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

February 14, 2023

During Tuesday, 40 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 13, 2023

On Monday, 42 companies hit new 52-week lows.

Via Benzinga

4 Analysts Have This to Say About Design Therapeutics ↗

June 10, 2022

Within the last quarter, Design Therapeutics (NASDAQ:DSGN) has observed the following analyst ratings:

Via Benzinga

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

February 08, 2023

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws ↗

January 19, 2023

San Diego, CA -- (SBWIRE) -- 01/19/2023 -- Design Therapeutics, Inc. is under investigation over potential securities laws violations.

Via SBWire

DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm

December 30, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday ↗

December 22, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

$7.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying ↗

December 21, 2022

Although US stocks closed mostly higher on Tuesday, there were a few notable insider trades.

Via Benzinga

S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results ↗

December 08, 2022

U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday.

Via Benzinga

Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

December 08, 2022

Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.

Via Benzinga

Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher ↗

December 08, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.

Via Benzinga

Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday ↗

December 08, 2022

U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Dow Rises 150 Points; US Jobless Claims Increase To 230,000 ↗

December 08, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining over 150 points on Thursday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 08, 2022

We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday!

Via InvestorPlace

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

December 07, 2022

From Design Therapeutics, Inc.

Via GlobeNewswire

Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday ↗

November 21, 2022

U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

November 03, 2022

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

October 17, 2022

Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022

From Design Therapeutics, Inc.

Via GlobeNewswire

Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session ↗

September 21, 2022

Gainers

Via Benzinga

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗

September 22, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022 ↗

June 10, 2022

Via Benzinga

Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗

September 20, 2022

Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗

May 02, 2022

Upgrades

Via Benzinga

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating ↗

January 19, 2022

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target. The analyst Madhu Kumar has...

Via Benzinga

46 Biggest Movers From Yesterday ↗

December 16, 2021

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...

Via Benzinga

54 Biggest Movers From Yesterday ↗

December 08, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...

Via Benzinga

56 Biggest Movers From Yesterday ↗

November 24, 2021

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating...

Via Benzinga

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗

September 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.